<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1069">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147233</url>
  </required_header>
  <id_info>
    <org_study_id>DX218</org_study_id>
    <nct_id>NCT05147233</nct_id>
  </id_info>
  <brief_title>OCS-01: A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</brief_title>
  <official_title>OCS-01: A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oculis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oculis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of OCS-01 Ophthalmic&#xD;
      Suspension versus placebo (vehicle) in the treatment of inflammation and pain following&#xD;
      cataract surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With an Absence of Anterior Chamber Inflammation</measure>
    <time_frame>Day 15</time_frame>
    <description>Absence of cells (i.e., score of ´0´) in the anterior chamber of the study eye at Day 15 (Visit 6)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With an Absence of Ocular Pain</measure>
    <time_frame>Day 4</time_frame>
    <description>Absence of pain (i.e., score of ´0´) in the study eye at Day 4 (Visit 4)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Disorders of the Eye Following Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>Active Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCS-01 (Ophthalmic Suspension) - topical use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone</description>
    <arm_group_label>Active Treatment Arm</arm_group_label>
    <other_name>OCS-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Placebo</intervention_name>
    <description>Placebo comparator</description>
    <arm_group_label>Vehicle Placebo Arm</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be planning to undergo unilateral cataract extraction via phacoemulsification and&#xD;
             posterior chamber intraocular lens (PCIOL) implantation in the study eye;&#xD;
&#xD;
          -  Have a pin-hole visual acuity (VA) without any other correction &gt; 20 letters&#xD;
             (approximately 20/400) in the operative eye and &gt; 35 letters (approximately 20/200) in&#xD;
             the fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study&#xD;
             (ETDRS) chart at Visit 1 (Day -1 to Day -28 [prior to surgery]).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have any intraocular inflammation (e.g. white blood cells or flare)present in either&#xD;
             eye at the Visit 1 (Day -1 to Day -28 [prior to surgery]) slit lamp examination;&#xD;
&#xD;
          -  Have a score &gt; 0 on the Ocular Pain Assessment at Visit 1 (Day -1 to Day -28 [prior to&#xD;
             surgery]) in the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oculis Investigative Site</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naleni Eigensatz</last_name>
    <phone>+41 21 711 3970</phone>
    <email>naleni.eigensatz@oculis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oculis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 24, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

